Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.
Ya ChenHongyu LiuNana HuYanan WangZhengyu YangJunqiang ZhangBao-Hui HanPublished in: Cancer medicine (2023)
Our study suggested that antiangiogenic-based therapy might improve PFS and OS in EGFR-mutant NSCLC patients with acquired resistance to osimertinib. Moreover, anlotinib-based therapy could be a promising effective treatment for this group of patients.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- advanced non small cell lung cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- clinical trial
- tyrosine kinase
- stem cells
- peritoneal dialysis
- prognostic factors
- cross sectional
- patient reported outcomes
- double blind
- replacement therapy
- combination therapy
- patient reported